Pay in 4 interest-free payments of $5.37 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
There are no hidden costs or additional charges
AOD-9604 (Anti-Obesity Drug 9604) is a modified peptide fragment consisting of the terminal 15 amino acids of human growth hormone (positions 176-191) with a tyrosine residue added at the N-terminus for stability
Conclusion In summary, the combination of GLP-1 medications and phentermine is a promising approach for individuals seeking to enhance their weight loss results
Natural flavors : Standard undisclosed natural flavoring concern lower risk in fruit-flavoured shots but unconfirmed
not FDA-approved as of January 2025 Best Phase 2 result / 24.2% mean body weight loss at 48 weeks (12 mg dose, N=338 trial) Extended estimate / 28.7% mean weight loss projected at 68 weeks in Phase 2 modeling Dosing schedule / Once weekly subcutaneous injection (doses 1 mg through 12 mg tested) Comparator benchmark / Semaglutide 2.4 mg: 14.9% at 68 weeks (STEP-1, N=1,961) Comparator benchmark / Tirzepatide 15 mg: 20.9% at 72 weeks (SURMOUNT-1, N=2,539) Primary side effects / Nausea, vomiting, diarrhea, constipation (dose-dependent) Phase 3 status / Phase 3 program (TRIUMPH trials) enrolling as of 2024 Manufacturer / Eli Lilly and Company What Is Retatrutide
US$ 23.87
US$ 29.93
US$ 25.46
US$ 21.83
US$ 20.33
US$ 29.36
US$ 27.57
